Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dsuvia

AstraZeneca AZ

Trials of AZ’s durvalumab restart as FDA hold is relaxed

Bleeding side effects in two head and neck cancer studies not attributed to the PD-L1 inhibitor

- PMLiVE

GSK files first application for triple COPD therapy

Submits combo in the US one year early to coincide with EU marketing application

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

- PMLiVE

Charting a course for expansion

David Meek on Ipsen's strategic pillars and hopes in oncology

- PMLiVE

A rock and a hard place

When insurance companies exclude drugs from their coverage

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

- PMLiVE

Pharma stocks rise after Donald Trump’s election win

But his exact healthcare and industry-focus remain uncertain

- PMLiVE

ApotheCom and Continuum Clinical expand strategic partnership

Team up to deliver real-world evidence-based integrated business solutions

- PMLiVE

Mylan facing US anticompetitive practice probe

Senate judiciary committee calls for fair competition review over EpiPen sales

- PMLiVE

Takeda launches drug discovery biotech

Hopes Bridge Medicines will streamline the development process

- PMLiVE

The Global Awards 2016 finalists announced

GSW Worldwide’s virtual reality epilepsy campaign among the 145 shortlisted entries

Sanofi reception

Manufacturing issues scupper Sanofi’s sarilumab launch plans

FDA turns down the rheumatoid arthritis drug’s marketing application after routine inspection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links